HCPLive

Atherosclerosis 
The MD Magazine Atherosclerosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Sponsored

Statins Plus PCSK9 Inhibitors Show Benefit for Plaque Reduction
If statins are good and PCSK9 inhibitors are better, how good will a combination be? Researchers reported today in a study called GLAGOV.
A PCSK9 inhibitor that reduces cholesterol by RNA interference instead of the monoclonal antibody approach appears effective and holds the promise of fewer injections and lower cost, researchers said today.
Systemic atherosclerosis causes peripheral artery disease, and these patients are at risk of cardiovascular death and stroke.
Younger patients with coronary heart disease who may have familial hypercholesterolemia need earlier diagnosis and treatment in order to reduce risk, according to the results of a recent study. FH is widely underdiagnosed, and is life-threatening.
Adding a PCSK9 inhibitor to apheresis therapy worked so well in reducing LDL in patients with familial hypercholesterolemia that two-thirds of the patients stopped getting apheresis.
A new meta-analysis of 102 randomized controlled diet trials found that consumption of polyunsaturated fat instead of carbohydrate or saturated fat reduces blood sugar levels and insulin resistance while also increasing the body’s ability to make insulin.
New research comparing patients and controls suggests that the body’s inflammatory response to psoriatic arthritis can lead to atherosclerosis and then to cardiovascular disease.
For patients eligible for a heart transplant getting on the list is just the first of many steps that need to happen before the procedure can be done.
While patients needing heart donations still drastically outnumbers the available organs for transplants recent changes in guidelines for transplantation have made the procedure available for an even wider patient population.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$